Stock SCTL SOCIETAL CDMO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Societal CDMO, Inc.

Equities

SCTL

US75629F1093

Market Closed - Nyse
Other stock markets
 04:00:00 2024-04-05 pm EDT 		5-day change 1st Jan Change
1.1 USD +0.92% Intraday chart for Societal CDMO, Inc. 0.00% +213.84%
Apr. 08 Societal CDMO, Inc. Announces Board and Committee Resignations CI
Apr. 08 Societal CDMO, Inc.(NasdaqCM:SCTL) dropped from NASDAQ Composite Index CI

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
  • According to Refinitiv, the company's ESG score for its industry is poor.

Strengths

  • The opinion of analysts covering the stock has improved over the past four months.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • Low profitability weakens the company.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
SOCIETAL CDMO, INC. Stock Societal CDMO, Inc.
+213.84% 116M
D+
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.61% 660B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+25.87% 562B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.24% 358B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.49% 322B
B-
ABBVIE INC. Stock AbbVie Inc.
+8.28% 297B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+7.09% 219B
B+
ROCHE HOLDING AG Stock Roche Holding AG
-9.12% 196B
A+
NOVARTIS AG Stock Novartis AG
+5.01% 199B
B-
PFIZER, INC. Stock Pfizer, Inc.
-8.75% 149B
C+
Investor Rating
Trading Rating
-
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy
  1. Stock Market
  2. Equities
  3. SCTL Stock
  4. Ratings Societal CDMO, Inc.